Pharmacogenetics study of anti-parkinson's disease drug levodopa

The association between polymorphisms of DRD2, DRD2, SLC6A3 and the levodopa response

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCS-12002720

Enrollment

Unknown

Registered

2012-11-26

Start date

2012-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

A:levodopa

Eligibility

Sex/Gender

All

Age

38 Years to 72 Years

Inclusion criteria

Inclusion criteria: 1. Parkinson's disease patients with motor symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait; 2. Patients two major motor symptoms as follow: static tremor, slowness of movement, Gear myotonia, and Posture reflex disorder; 3. Have response to levodopa; 4. with no other Parkinson-like syndrome or disease.

Exclusion criteria

Exclusion criteria: 1. Patient's sydrome was not root from cerebral trauma,cerebrovascular disease, brain tumor, virus infection or other nervous system disease; 2.Patients should not have gastrointestinal disorders or other disease; 3.Patients should not with heavy drinking and smoking or use other kind of CNS drugs.

Design outcomes

Primary

Measure	Time frame
Genotype;	—

Contacts

Public ContactJieLiu, Huizi Wu

huizijiaguo125@gmail.com+86 0731-84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026